HomeSearch results for “”Page 8

Search.

110 results for ""

Resource

Benefits of Bionical Emas – Phase 1 Services

 Resource

A guide to the Development Safety Update Report (DSUR)

 Page

Internship – KW

 Page

Internship – AR

 Page

Internship – MK

 Post

G1 Therapeutics, Inc and Bionical Emas Launch Expanded Access Program for Trilaciclib in Small Cell Lung Cancer in the United States

 Resource

Four things to think about: PVG in EAPs

By Nisha Vora - Senior Project Manager, Pharmacovigilance

 Resource

Nuances in Pharmacovigilance case processing in Early Access Programs

By Harry Woods - Pharmacovigilance Associate

How can we support you?

Our dedicated teams of experts are on hand to help should you require any additional resource or further information about our services.

Contact
COVID-19 Guidance & Measures

A statement from the Bionical Emas Group on guidance & measures regarding COVID-19 - read here

In relation to staff and visitor safety, we have full risk assessments in place for all of our workplaces. These risk assessments are revisited and updated regularly, to reflect changing risks, knowledge and circumstances, and to reflect evolving Government guidance. We have not placed the risk assessments here on the website as they would become out of date too quickly. However, you are welcome to email info@bionical-emas.com to request access to our most up to date risk assessments applicable to your needs. Please note that all our staff are notified of all applicable risk assessments and updates, along with ‘quick guides’ automatically via our e-learning system.